Refining Therapeutic Approaches in EGFR-Mutated Non–Small Cell Lung Cancer

Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss key factors guiding frontline therapy selection in EGFR-mutated NSCLC.

Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss treatment strategies for EGFR-mutated NSCLC with high-risk clinical features.

Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss the clinical role of amivantamab plus lazertinib in EGFR-mutated NSCLC.

Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss adverse event management with subcutaneous amivantamab.

Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss how frontline therapy selection influences sequencing in EGFR-mutated NSCLC.

Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, discuss toxicity considerations with ADCs and emerging therapies in EGFR-mutated NSCLC.